Jupiter Asset Management Ltd. Sells 122 Shares of Eli Lilly and Company (NYSE:LLY)

Jupiter Asset Management Ltd. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,059 shares of the company’s stock after selling 122 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Eli Lilly and Company were worth $17,393,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after acquiring an additional 21 shares during the period. Citizens National Bank Trust Department boosted its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $40,000. Mascagni Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $43,000. Finally, O Brien Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after acquiring an additional 12 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $761.47 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The stock has a fifty day moving average price of $775.51 and a two-hundred day moving average price of $800.23. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The firm has a market capitalization of $721.68 billion, a P/E ratio of 61.96, a P/E/G ratio of 1.08 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the prior year, the company earned $2.58 earnings per share. The business’s revenue was up 45.2% compared to the same quarter last year. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Hsbc Global Res cut Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Guggenheim increased their price objective on Eli Lilly and Company from $936.00 to $942.00 and gave the company a “buy” rating in a research report on Friday, July 11th. Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.